NuCana (NASDAQ:NCNA) Stock Price Down 2.4% – Should You Sell?

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) traded down 2.4% during mid-day trading on Thursday . The company traded as low as $1.60 and last traded at $1.60. Approximately 26,135 shares traded hands during trading, a decline of 46% from the average daily volume of 48,707 shares. The stock had previously closed at $1.64.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

NuCana Stock Down 2.4%

The company has a market cap of $6.66 million, a P/E ratio of -0.54 and a beta of 2.18. The business has a 50-day moving average price of $2.03 and a two-hundred day moving average price of $2.41.

NuCana (NASDAQ:NCNA) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $1.39.

Institutional Investors Weigh In On NuCana

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC boosted its holdings in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company’s stock after buying an additional 6,774 shares during the period. FNY Investment Advisers LLC owned approximately 33.33% of NuCana worth $36,000 as of its most recent SEC filing. 44.00% of the stock is currently owned by institutional investors.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.